An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.
Not Applicable
Completed
- Conditions
- Schizophrenia
- Interventions
- Device: CT-156
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT06486948
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psoriasis
Not Applicable
Active, not recruiting
- Conditions
- Atopic DermatitisPsoriasis
- Interventions
- Device: CT-100-004-ADevice: CT-100-004-B
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06275659
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia
Not Applicable
Completed
- Conditions
- Schizophrenia
- Interventions
- Device: CT-156-C-001
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT06136936
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer
Not Applicable
Completed
- Conditions
- Lung CancerBreast CancerMultiple Sclerosis
- Interventions
- Device: CT-100-D-004-ADevice: CT-100-D-004-B
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT06136923
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
Phase 3
Recruiting
- Conditions
- SchizophreniaNegative Symptoms in Schizophrenia
- Interventions
- Device: Study App
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06067984
- Locations
- 🇺🇸
Click Therapeutics, New York City, New York, United States
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Phase 3
Completed
- Conditions
- HeadacheEpisodic MigraineHeadache, MigraineMigraine
- Interventions
- Device: Click Digital Therapeutic
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06004388
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Phase 3
Completed
- Conditions
- Headache, MigraineMigraineEpisodic MigraineHeadache
- Interventions
- Device: ReMMi-D Digital Therapeutic
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 558
- Registration Number
- NCT05853900
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
Phase 3
Recruiting
- Conditions
- Schizophrenia
- Interventions
- Device: Digital Therapeutic
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 432
- Registration Number
- NCT05838625
- Locations
- 🇺🇸
Investigational center, Salt Lake City, Utah, United States
🇺🇸Click Therapeutics, New York, New York, United States
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training
Not Applicable
Completed
- Conditions
- Irritable Bowel SyndromeDiabetic NeuropathyFibromyalgiaRheumatoid Arthritis
- Interventions
- Device: DiNaMo Study AppDevice: Placebo App
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT05573685
- Locations
- 🇺🇸
Click Therapeutics, New York, New York, United States
7-week Study With CT-155 in People With Schizophrenia
Not Applicable
Completed
- Conditions
- Schizophrenia
- Interventions
- Device: CT-155 smartphone app
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Click Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05486312
- Locations
- 🇺🇸
CT-155 Study Center, Oklahoma City, Oklahoma, United States
🇺🇸CT-155 study Center, Staten Island, New York, United States
© Copyright 2025. All Rights Reserved by MedPath